Curcumin: Getting Back to the Roots
SHISHIR SHISHODIA
Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Search for more papers by this authorGAUTAM SETHI
Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Search for more papers by this authorCorresponding Author
BHARAT B. AGGARWAL
Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Address for correspondence: Bharat B. Aggarwal, Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Box 143, 1515 Holcombe Boulevard, Houston, TX 77030. Voice: 713–792-3503/6459; fax: 713–794-1613; E-mail: [email protected]Search for more papers by this authorSHISHIR SHISHODIA
Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Search for more papers by this authorGAUTAM SETHI
Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Search for more papers by this authorCorresponding Author
BHARAT B. AGGARWAL
Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Address for correspondence: Bharat B. Aggarwal, Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Box 143, 1515 Holcombe Boulevard, Houston, TX 77030. Voice: 713–792-3503/6459; fax: 713–794-1613; E-mail: [email protected]Search for more papers by this authorAbstract
The use of turmeric, derived from the root of the plant Curcuma longa, for treatment of different inflammatory diseases has been described in Ayurveda and in traditional Chinese medicine for thousands of years. The active component of turmeric responsible for this activity, curcumin, was identified almost two centuries ago. Modern science has revealed that curcumin mediates its effects by modulation of several important molecular targets, including transcription factors (e.g., NF-κB, AP-1, Egr-1, β-catenin, and PPAR-γ), enzymes (e.g., COX2, 5-LOX, iNOS, and hemeoxygenase-1), cell cycle proteins (e.g., cyclin D1 and p21), cytokines (e.g., TNF, IL-1, IL-6, and chemokines), receptors (e.g., EGFR and HER2), and cell surface adhesion molecules. Because it can modulate the expression of these targets, curcumin is now being used to treat cancer, arthritis, diabetes, Crohn's disease, cardiovascular diseases, osteoporosis, Alzheimer's disease, psoriasis, and other pathologies. Interestingly, 6-gingerol, a natural analog of curcumin derived from the root of ginger (Zingiber officinalis), exhibits a biologic activity profile similar to that of curcumin. The efficacy, pharmacologic safety, and cost effectiveness of curcuminoids prompt us to “get back to our roots”
REFERENCES
- 1 Aggarwal, B.B., A. Kumar & A.C. Bharti. 2003. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 23: 363–398.
- 2 Cheng, A.L., C.H. Hsu, J.K. Lin, et al. 2001. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 21: 2895–2900.
- 3 Ammon, H.P. & M.A. Wahl. 1991. Pharmacology of Curcuma longa. Planta Med. 57: 1–7.
- 4 Khopde, S.M., K.I. Priyadarsini, P. Venkatesan, et al. 1999. Free radical scavenging ability and antioxidant efficiency of curcumin and its substituted analogue. Biophys. Chem. 80: 85–91.
- 5 Adams, B.K., J. Cai, J. Armstrong, et al. 2005. EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anticancer Drugs 16: 263–275.
- 6 Aggarwal, B.B., A. Kumar, M.S. Aggarwal, et al. 2005. Curcumin derived from turmeric (Curcuma longa): a spice for all seasons. In Phytochemicals in Cancer Chemoprevention. P.D. Debasis Bagchi & H.G. Preuss, Eds.:349-387. CRC Press. New York.
- 7 Heng, M.C., M.K. Song, J. Harker, et al. 2000. Drug-induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parameters. Br. J. Dermatol. 143: 937–949.
- 8 Tourkina, E., P. Gooz, J.C. Oates, et al. 2004. Curcumin-induced apoptosis in scleroderma lung fibroblasts: role of protein kinase cepsilon. Am. J. Respir. Cell Mol. Biol. 31: 28–35.
- 9 Yang, F., G.P. Lim, A.N. Begum, et al. 2005. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280: 5892–5901.
- 10 Ukil, A., S. Maity, S. Karmakar, et al. 2003. Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br. J. Pharmacol. 139: 209–218.
- 11 Egan, M.E., M. Pearson, S.A. Weiner, et al. 2004. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 304: 600–602.
- 12 Bharti, A.C., N. Donato & B.B. Aggarwal. 2003. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J. Immunol. 171: 3863–3871.
- 13 Xu, J., Y. Fu & A. Chen. 2003. Activation of peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of curcumin on rat hepatic stellate cell growth. Am. J. Physiol. Gastrointest. Liver Physiol. 285: G20–30.
- 14 Bharti, A.C., N. Donato, S. Singh, et al. 2003. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 101: 1053–1062.
- 15 Mukhopadhyay, A., C. Bueso-Ramos, D. Chatterjee, et al. 2001. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 20: 7597–7609.
- 16 Mukhopadhyay, A., S. Banerjee, L.J. Stafford, et al. 2002. Curcumin-induced suppression of cell proliferation correlates with donregulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene 21: 8852–8862.
- 17 Khopde, S.M., K.I. Priyadarsini, S.N. Guha, et al. 2000. Inhibition of radiation-induced lipid peroxidation by tetrahydrocurcumin: possible mechanisms by pulse radiolysis. Biosci. Biotechnol. Biochem. 64: 503–509.
- 18 Venkatesan, P., M.K. Unnikrishnan, S.M. Kumar, et al. 2003. Effect of curcumin analogues on oxidation of haemoglobin and lysis of erythrocytes. Curr. Sci. 84: 74–78.
- 19 Rao, T.S., N. Basu & H.H. Siddiqui. 1982. Anti-inflammatory activity of curcumin analogues. Indian J. Med. Res. 77: 574–578.
- 20 Kumar, A.P., G.E. Garcia, R. Ghosh, et al. 2003. 4-Hydroxy-3-methoxybenzoic acid methyl ester: a curcumin derivative targets Akt/NF kappa B cell survival signaling pathway: potential for prostate cancer management. Neoplasia 5: 255–266.
- 21 Hahm, E.R., G. Cheon, J. Lee, et al. 2002. New and known symmetrical curcumin derivatives inhibit the formation of Fos-Jun-DNA complex. Cancer Lett. 184: 89–96.
- 22 Barthelemy, S., L. Vergnes, M. Moynier, et al. 1998. Curcumin and curcumin derivatives inhibit Tat-mediated transactivation of type 1 human immunodeficiency virus long terminal repeat. Res. Virol. 149: 43–52.
- 23 Douglas, D.E. 1993. 4,4′-Diacetyl curcumin: in-vitro histamine-blocking activity. J. Pharm. Pharmacol. 45: 766.
- 24 John, V.D., G. Kuttan & K. Krishnankutty. 2002. Anti-tumour studies of metal chelates of synthetic curcuminoids. J. Exp. Clin. Cancer Res. 21: 219–224.
- 25 Shim, J.S., D.H. Kim, H.J. Jung, et al. 2002. Hydrazinocurcumin, a novel synthetic curcumin derivative, is a potent inhibitor of endothelial cell proliferation. Bioorg. Med. Chem. 10: 2439–2444.
- 26 Rukkumani, R., K. Aruna, P.S. Varma, et al. 2004. Comparative effects of curcumin and an analog of curcumin on alcohol and PUFA induced oxidative stress. J. Pharm. Pharm. Sci. 7: 274–283.
- 27 Mishra, S., S. Tripathi & K. Misra. 2002. Synthesis of a novel anticancer prodrug designed to target telomerase sequence. Nucleic Acids Res. (Suppl.) 2: 277–278.
- 28 Selvam, C., S.M. Jachak, R. Thilagavathi, et al. 2005. Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory agents. Bioorg. Med. Chem. Lett. 15: 1793–1797.
- 29 Gomes Dde, C., L.V. Alegrio, M.E. de Lima, et al. 2002. Synthetic derivatives of curcumin and their activity against Leishmania amazonensis. Arzneimittelforschung 52: 120–124.
- 30 Dinkova-Kostova, A.T. & P. Talalay. 1999. Relation of structure of curcumin analogs to their potencies as inducers of Phase 2 detoxification enzymes. Carcinogenesis 20: 911–914.
- 31 Tonnesen, H.H. & J.V. Greenhill. 1992. Studies on curcumin and curcuminoids XXII: curcumin as a reducing agent and as a radical scavenger. Int. J. Pharm. 87: 79–87.
- 32 Vajragupta, O., P. Boonchoong & L.J. Berliner. 2004. Manganese complexes of curcumin analogues: evaluation of hydroxyl radical scavenging ability, superoxide dismutase activity and stability towards hydrolysis. Free Radic. Res. 38: 303–314.
- 33 Venkatesan, P. & M.N. Rao. 2000. Structure-activity relationships for the inhibition of lipid peroxidation and the scavenging of free radicals by synthetic symmetrical curcumin analogues. J. Pharm. Pharmacol. 52: 1123–1128.
- 34 Sreejayan, N. & M.N. Rao. 1996. Free radical scavenging activity of curcuminoids. Arzneimittelforschung 46: 169–171.
- 35 Ahsan, H., N. Parveen, N.U. Khan, et al. 1999. Pro-oxidant, anti-oxidant and cleavage activities on DNA of curcumin and its derivatives demethoxycurcumin and bisdemethoxycurcumin. Chem. Biol. Interact. 121: 161–175.
- 36 Kawashima, H., K. Akimoto, S. Jareonkitmongkol, et al. 1996. Inhibition of rat liver microsomal desaturases by curcumin and related compounds. Biosci. Biotechnol. Biochem. 60: 108–110.
- 37 Simon, A., D.P. Allais, J.L. Duroux, et al. 1998. Inhibitory effect of curcuminoids on MCF-7 cell proliferation and structure-activity relationships. Cancer Lett. 129: 111–116.
- 38 Robinson, T.P., T. Ehlers, I.R. Hubbard, et al. 2003. Design, synthesis, and biological evaluation of angiogenesis inhibitors: aromatic enone and dienone analogues of curcumin. Bioorg. Med. Chem. Lett. 13: 115–117.
- 39 Kim, S.O., J.K. Kundu, Y.K. Shin, et al. 2005. [6]-Gingerol inhibits COX-2 expression by blocking the activation of p38 MAP kinase and NF-kappaB in phorbol ester-stimulated mouse skin. Oncogene 24: 2558–2567.
- 40 Keum, Y.S., J. Kim, K.H. Lee, et al. 2002. Induction of apoptosis and caspase-3 activation by chemopreventive [6]-paradol and structurally related compounds in KB cells. Cancer Lett. 177: 41–47.
- 41 Mahady, G.B., S.L. Pendland, G.S. Yun, et al. 2003. Ginger (Zingiber officinale Roscoe) and the gingerols inhibit the growth of Cag A+ strains of Helicobacter pylori. Anticancer Res. 23: 3699–3702.
- 42 Masuda, T., H. Matsumura, Y. Oyama, et al. 1998. Synthesis of (+/−)-cassumunins A and B, new curcuminoid antioxidants having protective activity of the living cell against oxidative damage. J. Nat. Prod. 61: 609–613.
- 43 Hong, J., M. Bose, J. Ju, et al. 2004. Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase. Carcinogenesis 25: 1671–1679.
- 44 Miyoshi, N., Y. Nakamura, Y. Ueda, et al. 2003. Dietary ginger constituents, galanals A and B, are potent apoptosis inducers in human T lymphoma Jurkat cells. Cancer Lett. 199: 113–119.
- 45 Pan, M.H., W.L. Chang, S.Y. Lin-Shiau, et al. 2001. Induction of apoptosis by garcinol and curcumin through cytochrome c release and activation of caspases in human leukemia HL-60 cells. J. Agric. Food Chem. 49: 1464–1474.
- 46 Chainy, G.B., S.K. Manna, M.M. Chaturvedi, et al. 2000. Anethole blocks both early and late cellular responses transduced by tumor necrosis factor: effect on NF-kappaB, AP-1, JNK, MAPKK and apoptosis. Oncogene 19: 2943–2950.
- 47 Chun, K.S., J.Y. Kang, O.H. Kim, et al. 2002. Effects of yakuchinone A and yakuchinone B on the phorbol ester-induced expression of COX-2 and iNOS and activation of NF-kappaB in mouse skin. J. Environ. Pathol. Toxicol. Oncol. 21: 131–139.
- 48 Flynn, D.L., M.F. Rafferty & A.M. Boctor. 1986. Inhibition of 5-hydroxy-eicosatetraenoic acid (5-HETE) formation in intact human neutrophils by naturally-occurring diarylheptanoids: inhibitory activities of curcuminoids and yakuchinones. Prostaglandins Leukot. Med. 22: 357–360.
- 49 Fujisawa, S., T. Atsumi, M. Ishihara, et al. 2004. Cytotoxicity, ROS-generation activity and radical-scavenging activity of curcumin and related compounds. Anticancer Res. 24: 563–569.
- 50 Pan, M.H., T.M. Huang & J.K. Lin. 1999. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab. Dispos. 27: 486–494.
- 51 Ishida, J., H. Ohtsu, Y. Tachibana, et al. 2002. Antitumor agents. Part 214: synthesis and evaluation of curcumin analogues as cytotoxic agents. Bioorg. Med. Chem. 10: 3481–3487.
- 52 Srivivasan, A., V.P. Menon, V. Periaswamy, et al. 2003. Protection of pancreatic beta-cell by the potential antioxidant bis-o-hydroxycinnamoyl methane, analogue of natural curcuminoid in experimental diabetes. J. Pharm. Pharm. Sci. 6: 327–333.
- 53 Ohtsu, H., Z. Xiao, J. Ishida, et al. 2002. Antitumor agents. 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents. J. Med. Chem. 45: 5037–5042.